penbex 100,0, suspensie
invesa, spania - penicilin - suspensie - крупного рогатого скота, О.В. ине, suine, cîini, pisici, cabaline
celestoderm-v 0,1% unguent
schering-plough central east ag - betamethasonum - unguent - 0,1%
meloflam 15 mg comprimate
egis pharmaceuticals plc - meloxicamum - comprimate - 15 mg
oxaliplatin actavis 5 mg/ml
actavis s.r.l. - oxaliplatinum - pulb. pt. sol. perf. - 5mg/ml - alte antineoplazice compusi de platina
sindronat 300 mg/5 ml
actavis s.r.l. - acidum clodronicum - conc. pt. sol. perf. - 300mg/5ml - med. ce influenteaza structura osoasa si mineralizarea bifosfonati
sindaxel 6 mg/ml
actavis s.r.l. - paclitaxelum - conc. pt. sol. perf. - 6mg/ml - alcaloizi din plante si alte produse naturale taxani
carboplatin actavis 10mg/ml
actavis s.r.l. - carboplatinum - conc. pt. sol. perf. - 10mg/ml - alte antineoplazice compusi de platina
melphalan hydrochloride 50 mg
cn unifarm s.a. - melphalanum - pulb+solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard
bondenza (previously ibandronic acid roche)
roche registration ltd. - acidul ibandronic - osteoporoza, postmenopauză - medicamente pentru tratamentul bolilor osoase - tratamentul osteoporozei la femei în postmenopauză cu risc crescut de fracturi. reducerea riscului de fracturi vertebrale a fost demonstrată. eficacitatea pe femurală-gât fracturi nu a fost stabilită.
vidaza
bristol-myers squibb pharma eeig - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.